You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 12 No. 5, May 1965 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (34)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Use of an Oral Corticosteroid In the Treatment Of Multiple Sclerosis

A Double-Blind Study

WALLACE W. TOURTELLOTTE, MD; ARMIN F. HAERER, MD

Arch Neurol. 1965;12(5):536-545.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE PURPOSE of this report is to present the results of a double-blind drug trial in which an oral corticosteroid, methylprednisolone (Medrol), was compared to oral cyanocobalamin (vitamin B12) in patients with multiple sclerosis.

This pair of drugs was chosen for comparison for several reasons. If multiple sclerosis is a peculiar auto-immune disease related to the myelin of the brain, then it might be reasonable to expect that corticosteroids may favorably alter the course of the disease.1 A number of reports in the recent literature have dealt with clinical trials of corticosteroids and corticotropin (ACTH) in the treatment of patients with multiple sclerosis. Studies by Alexander et al on corticotropin,2,3 which did not include modern statistical designs such as randomization of administration of placebo and corticotropin and a double-blind technique, have indicated a favorable response. Miller et al,4 utilizing a modern statistical design, also concluded that corticotropin . . . [Full Text PDF of this Article]


Author Affiliations

ANN ARBOR, MICH

From the Department of Neurology, University of Michigan.


Footnotes

Submitted for publication Dec 5, 1964; accepted Jan 22, 1965.

Present address (Dr. Haerer): 5803A Billhymer, Fort Knox, Ky.

Reprint requests to Department of Neurology, University of Michigan Medical Center, Ann Arbor, Mich 48104 (Dr. Tourtellotte).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1965 American Medical Association. All Rights Reserved.